Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease

Table 1 Sample-sets used in the Epistasis Project

Group	Geographical Region*	Subjects^†	Numbers	% women	p (AD vs controls)	Median age^‡ (interquartile range)	p (AD vs controls)
Bonn	Bonn and Mainz, Germany	Clinical AD	259	61.4		71.0 (65.1–77.5)
		Screened controls	232	56.9	0.31	67.8 (64.4–76.1)	0.11
Bristol	South-West England	Autopsy AD	200	45.0		80.4 (75.6–86.0)
		Autopsy controls	57	40.4	0.55	77.9 (72.8–82.9)	0.12
Nottingham	Cambridge, England	Autopsy AD	104	48.1		78.7 (70.8–84.6)
		Autopsy controls	107	34.6	0.051	72.5 (65.6–80.0)	< 0.001
OPTIMA	Oxford, England	Autopsy AD	163	54.6		79.5 (72.4–85.2)
		Clinical AD	87	54.0		79.1 (73.4–84.8)
		Screened controls	261	53.6	0.93	78.9 (72.9–83.8)	0.54
Oviedo	Asturias, Spain	Clinical AD	202	69.8		78.4 (74.8–82.8)
		Screened controls	131	61.8	0.15	69.7 (63.5–74.5)	< 0.001
Rotterdam	Rotterdam (Ommord), the Netherlands	Clinical AD	391	74.9		86.6 (82.2–91.6)
		Screened controls	5,111	57.7	< 0.001	76.9 (71.7–83.0)	< 0.001
Santander	Cantabria, Spain	Clinical AD	351	65.0		75.5 (70.8–78.9)
		Screened controls	396	68.9	0.27	80.9 (74.7–85.6)	< 0.001
Totals		Total AD	1,757	62.4		79.0 (73.0–85.2)
		Total controls	6,295	57.7		76.9 (71.3–83.0)

AD = Alzheimer's disease
*from which the samples were drawn.
^†Clinical AD cases were diagnosed as "probable AD" by NINCDS-ADRDA criteria [12]; autopsy AD cases were diagnosed as "definite" or "probable" by CERAD criteria [11]; screened controls were free of cognitive impairment; autopsy controls were free of pathology consistent with AD or other dementias; all controls were ≥ 60 years of age.
^‡Age at death or last examination.

ISSN: 1742-2094